AUA Guidelines Strengthen Recommendation for Aquablation® Therapy

PROCEPT BioRobotics (Nasdaq: PRCT) announced that updated American Urological Association (AUA) guidelines strengthen the recommendation for Aquablation therapy as a surgical option for men with BPH and prostate volumes of 30–80 mL.

Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT) announced that updated American Urological Association (AUA) guidelines strengthen the recommendation for Aquablation therapy as a surgical option for men with BPH and prostate volumes of 30–80 mL. The AUA also recognizes Aquablation may be offered for larger prostates of 80–150 mL.

The update reflects maturing clinical evidence, including randomized trials showing durable urinary symptom and flow improvements through five years across a broad range of prostate sizes. Aquablation is supported by trials against TURP and laser enucleation. Earlier this year, European Association of Urology (EAU) guidelines also issued a strong recommendation for Aquablation.

Positive

• AUA guidelines strengthen recommendation for Aquablation therapy in 30–80 mL prostates
• AUA recognizes Aquablation may be offered for larger 80–150 mL prostates
• Randomized clinical trials show durable symptom and flow improvements through five years
• Trials include comparisons against TURP and laser enucleation procedures
• EAU guidelines give a strong recommendation for Aquablation in BPH treatment

Negative

• None.

Argus May 14 session

+2.65% close to close Open Argus

Details

News Market Reaction – PRCT

On May 14, the day this news came out, PRCT closed 2.65% above the previous close.

Data tracked by StockTitan Argus for the May 14 session.

Key Figures

Primary prostate volume range: 30–80 mL Extended prostate volume range: 80–150 mL Durability timeframe: five years

Primary prostate volume range

30–80 mL

AUA guideline range where Aquablation should be offered as surgical option

Extended prostate volume range

80–150 mL

AUA guideline range where Aquablation may be offered in larger prostates

Durability timeframe

five years

Randomized clinical trial data showing durable urinary symptom and flow improvements

Historical Context

5 past events · Latest: Apr 30

5 events

1. Apr 30

   Investor conferences

   24h Move

   +2.5%

   Announcement of participation in three upcoming investor conferences in 2026.

2. Apr 29

   Earnings results

   24h Move

   +10.7%

   Q1 2026 revenue growth, higher procedures, solid gross margin and reaffirmed guidance.

3. Apr 09

   Earnings date notice

   24h Move

   -0.3%

   Scheduling and call details for the upcoming Q1 2026 earnings report.

4. Mar 23

   Guideline upgrade

   24h Move

   +0.9%

   EAU upgrading Aquablation therapy to a strong surgical recommendation for BPH.

5. Mar 12

   Product launch

   24h Move

   -6.0%

   International launch of HYDROS, an AI-enabled robotic system for Aquablation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), randomized clinical trial, laser enucleation

4 terms

lower urinary tract symptoms (LUTS) medical

"for the management of lower urinary tract symptoms (LUTS) attributed to benign"

Lower urinary tract symptoms (LUTS) are a group of problems affecting how people store and pass urine, such as frequent urination, urgency, weak stream, or difficulty starting and stopping. Think of it like a plumbing system that’s losing pressure or becoming unreliable; these symptoms can be chronic and widespread, driving demand for medications, devices, and procedures and shaping clinical trial design, regulatory review, and long-term revenue prospects for healthcare companies.

benign prostatic hyperplasia (BPH) medical

"lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH)"

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that can squeeze the urethra and cause urinary symptoms such as weak stream, frequent nighttime urination, or difficulty starting. Investors care because BPH is common in older men, creating steady demand for medications, medical devices, and procedures; changes in treatment options, regulatory approvals, or trial results can affect companies that sell therapies — think of it as a market driven by a widespread, age-related ‘traffic jam’ in the urinary system.

randomized clinical trial medical

"including randomized clinical trial data demonstrating durable improvements in urinary"

A randomized clinical trial is a medical study in which people are assigned by chance—like flipping a coin or shuffling a deck—into different groups that receive a treatment, a different treatment, or a non‑treatment for comparison. It matters to investors because these trials provide the strongest, least biased evidence about whether a drug or medical device actually works and is safe; clear trial results can drive regulatory approval, sales forecasts, and company value.

laser enucleation medical

"trial data against TURP and laser enucleation, reinforcing its ability to deliver"

Laser enucleation is a minimally invasive surgical technique that uses focused laser energy to remove diseased tissue by separating it from the surrounding organ, most commonly used to treat an enlarged prostate. Think of it like peeling the unwanted section away from an orange without cutting the skin — it aims to reduce bleeding, shorten hospital stays, and speed recovery. Investors care because the procedure drives demand for specific surgical devices, affects hospital costs and reimbursement rates, and can influence market share and regulatory outlook for medical-device makers and healthcare providers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Update reflects growing clinical evidence and expanded adoption in practice

SAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with prostate volumes 30–80 mL. The guidelines also recognize that Aquablation therapy may be offered in larger prostates (80–150 mL), expanding its use across a broader patient population.

The update reflects the maturity of the clinical evidence supporting Aquablation therapy, including randomized clinical trial data demonstrating durable improvements in urinary symptoms and flow rates through five years, as well as expanding use across a broad range of prostate sizes.

“This milestone reflects the growing adoption of Aquablation therapy in clinical practice and the durable outcomes demonstrated across a broad range of patients,” said Larry Wood, President and Chief Executive Officer of PROCEPT BioRobotics.

“The AUA guidelines now state that clinicians should offer Aquablation therapy, reflecting the strength and maturity of the clinical evidence supporting its use,” said Ricardo Gonzalez, MD, Houston Methodist. “Aquablation is supported by randomized clinical trial data against TURP and laser enucleation, reinforcing its ability to deliver durable outcomes for men with BPH.”

This development builds on recent global guideline momentum for Aquablation therapy, including the European Association of Urology (EAU) guidelines, which were updated earlier this year to include a strong recommendation for Aquablation therapy as a surgical treatment option for men with BPH.

About PROCEPT BioRobotics^® Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics manufactures the AQUABEAM^® and HYDROS^® Robotic Systems. The HYDROS Robotic System is the only AI-powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with approximately 250 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those anticipated or implied in such statements. PROCEPT BioRobotics undertakes no obligation to publicly update or revise any forward-looking statements.

Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Media Contact:
Matt Basco
Vice President, Investor Relations and Business Operations
PROCEPT BioRobotics
m.bacso@procept-biorobotics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What change did the AUA guidelines make regarding Aquablation therapy for PRCT in May 2026?

The AUA guidelines now give a stronger recommendation for Aquablation therapy as a surgical option for men with BPH and 30–80 mL prostates. According to PROCEPT BioRobotics, this reflects growing clinical evidence and greater adoption in urology practice.

For what prostate size range do the updated AUA guidelines support Aquablation therapy (PRCT)?

The updated AUA guidelines recommend Aquablation therapy for men with prostate volumes of 30–80 mL and recognize it may be offered for 80–150 mL prostates. According to PROCEPT BioRobotics, this expands Aquablation’s potential use across a broader BPH patient population.

What clinical evidence supports Aquablation therapy mentioned by PROCEPT BioRobotics (PRCT)?

Aquablation therapy is supported by randomized clinical trials showing durable improvements in urinary symptoms and flow rates through five years. According to PROCEPT BioRobotics, these trials include comparisons against TURP and laser enucleation across a wide range of prostate sizes in men with BPH.

How do European guidelines view Aquablation therapy for BPH and PRCT’s technology?

European Association of Urology guidelines provide a strong recommendation for Aquablation therapy as a surgical option for men with BPH. According to PROCEPT BioRobotics, this global guideline momentum complements the strengthened AUA recommendation and highlights broad professional support for the procedure.

What does the stronger Aquablation guideline support mean for PROCEPT BioRobotics (PRCT) investors?

Stronger guideline support signals broader clinical recognition of Aquablation, potentially influencing its use in BPH surgery. According to PROCEPT BioRobotics, both AUA and EAU guidelines now recommend Aquablation, which may be relevant for investor views on the therapy’s clinical positioning.